Thus, silencing PRMT5 in CRC cells reduces FGFR3 expression, leading to the repression of AKT and ERK and subsequent inhibition of mTOR through the AKT/mTOR or ERK pathway. The gene discussed is MTOR; the disease is colorectal carcinoma.